This site uses cookies to store information on your computer. Learn more x

DSM in Medical

Extracellular Matrix (ECM) technology

ECM technology used to reinforce and repair soft tissue defects

DSM uses our proprietary OPTRIX™ technology to process porcine derived tissues, which results in biologic surgical grafts that are used to reinforce and repair soft tissue defects. Our ability to apply this technology to multiple tissue sources enables us to create customized soft tissue regeneration products for a variety of clinical applications.
440-ecm

OPTRIX™ tissue processing technology

The OPTRIX™ process gently disinfects tissues, inactivates viruses, and removes cells while preserving the natural, open pore structure of the collagen matrix and maintains the extracellular matrix (ECM) components.* The gentle and selective nature of the process results in products with strength, a porous scaffold structure allowing for cell ingrowth and  retention of ECM components* may facilitate rapid cell infiltration and revascularization.

*The effect of these components on the performance of the extracellular matrix products has not been clinically evaluated.

Extracellular Matrices (ECMs)

An ECM in its natural form is the combination of collagen, proteins, proteoglycans, glycosaminoglycans, and other biological materials produced by cells that form the structural and functional components of all soft tissues and organs in the body. The ECM serves as a structural scaffold with receptor sites to orient cells, and a communication portal that provides a means for cells to communicate via signaling factors to regulate a variety of molecular functions. The ECM fundamentally controls the way in which mammals respond to injury and serves as an inductive scaffold for tissue repair and regeneration. DSM ECM products are acellular scaffolds and do not function as natural soft tissues.

Demonstrated in-vitro** biologic activity1

DSM invests in comprehensive analysis of our extracellular matrices to validate the gentle selectivity of the OPTRIX™ process. Material characterization shows we have preserved the collagen structure while maintaining natural ECM components* including elastin, fibronectin, laminin, glycosaminoglycans, proteoglycans, growth factors, and cytokines.1-3 In vitro testing demonstrates the potential for increased biologic activity:1 **

  • Greater retention of TGF-β and VEGF relative to incumbent commercial products2, 3
  • More rapid cell infiltration of the mesothelium ECM compared to dermis xenograft products3

*The effect of these components on the performance of the extracellular matrix products has not been clinically evaluated.

**In-vitro results are not necessarily indicative of clinical performance.

Potential clinical applications

At DSM we know that every clinical need poses unique challenges and requires specialized tools. We have developed two ECM products to provide a range of handling properties and cell infiltration characteristics; porcine dermis for robust strength and porcine mesothelium for enhanced drape and conformability. The versatility of our OPTRIX™ processing methods provides the opportunity to customize products for a variety of soft tissue reinforcement needs, such as:

  • Abdominal wall reconstruction 
  • Suture/staple line reinforcement 
  • Plastic and reconstructive surgery
  • Hernia repair 
  • Rotator cuff repair 
  • Pelvic floor reconstruction

References

  1. BioMaterials. 2010 Sep;31(27):6934-40.
  2. BioMaterials. 2010 Sep;31(26):6730-7.
  3. DSM, Data on File. Animal and bench top test results are not necessarily indicative of clinical performance.

Medeor®, Meso BioMatrix®, Meso Wound Matrix™ and OPTRIX™ are trademarks of DSM.

 

  • Soft tissue repair:
    • Achilles
    • Biceps
    • Hernia
    • Muscle flap reinforcement
    • Patellar
    • Plastic & reconstructive surgery
    • Quadriceps tendons
    • Rotator cuff
    • Suture line reinforcement
  • Dental guided membranes

  • Advanced wound dressings